The KLF12 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human colorectal adenocarcinoma cell line HT29, designed to disrupt the KLF12 gene. This loss-of-function model enables researchers to investigate the functional consequences of KLF12 ablation in a colorectal cancer context. The polyclonal population, generated by non-homologous end joining following Cas9-mediated double-strand breaks, provides a heterogeneous pool of KLF12 knockout cells, reflecting a range of editing outcomes. This product serves as a versatile tool for studying transcriptional regulation, tumor suppression mechanisms, and signal transduction independently of clonal variation, facilitating robust and reproducible experimental designs.
HT29 cells are an extensively characterized human colorectal adenocarcinoma cell line exhibiting epithelial morphology and originating from a primary colon adenocarcinoma. These cells harbor mutations in key oncogenes and tumor suppressors, including APC and TP53, and display a moderately differentiated phenotype. HT29 cells are widely employed in cancer research to model colorectal tumor biology, epithelial-mesenchymal transition, drug response, and signaling pathway crosstalk. Their ability to form monolayers and three-dimensional structures makes them suitable for both standard two-dimensional culture and organoid-based assays, offering a physiologically relevant platform for evaluating gene function in colorectal oncogenesis.
KLF12 encodes a member of the Kr??ppel-like factor family of transcription factors that functions as a transcriptional repressor. It recruits corepressor complexes containing CtBP1, HDAC1, and SIN3A through a conserved PLDLS motif to silence target gene expression. KLF12 is a downstream effector of TGF-beta signaling, activated by TGF-beta1 via SMAD2/3, and it negatively regulates AP-2 transcription factor activity. Key targets repressed by KLF12 include AP-2 responsive genes, as well as CDKN1A (p21) and BAX, linking KLF12 to cell cycle arrest and apoptosis. Thus, KLF12 acts as a mediator of TGF-beta-induced growth inhibition, and its loss disrupts these tumor-suppressive pathways, promoting uncontrolled proliferation.
In the HT29 colorectal cancer background, loss of KLF12 function provides a disease-relevant model for studying tumor progression, as KLF12 downregulation has been associated with enhanced malignancy in colorectal, gastric, and glioblastoma cancers. The interplay between KLF12 and the TGF-beta and Wnt signaling pathways is particularly important in colon carcinogenesis, where aberrant signaling drives epithelial-mesenchymal transition, invasion, and metastasis. By eliminating KLF12 expression, researchers can dissect its role in modulating these pathways and assess how its absence affects downstream effectors and cellular behaviors such as adhesion, migration, and survival, thereby mimicking aspects of aggressive colorectal adenocarcinoma.
The KLF12 Knockout HT29 Polyclonal Cells are suitable for a broad range of experimental applications. They can be used in Western blot and RT-qPCR assays to confirm gene disruption and assess compensatory changes in pathway components. Reporter gene assays enable dissection of KLF12??s repressor activity on AP-2 and other targets, while chromatin immunoprecipitation (ChIP-qPCR) can map corepressor occupancy changes. Functional studies may include cell proliferation, colony formation, apoptosis, and migration/invasion assays to evaluate tumorigenic properties. These cells also serve as a platform for drug target validation and for screening compounds that modulate TGF-beta or Wnt signaling. For additional information or technical support, please contact Ascent Research.
